These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 16614631)

  • 21. Lipodystrophy in HIV/AIDS patients with different levels of physical activity while on antiretroviral therapy.
    Segatto AF; Freitas Junior IF; Santos VR; Alves KC; Barbosa DA; Portelinha Filho AM; Monteiro HL
    Rev Soc Bras Med Trop; 2011; 44(4):420-4. PubMed ID: 21860886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of HIV infection and antiretroviral therapy on the mitochondrial membrane potential of peripheral mononuclear cells.
    Sternfeld T; Schmid M; Tischleder A; Mudra S; Schlamp A; Kost BP; Gruber R; Youle M; Bogner JR; Goebel FD
    Antivir Ther; 2007; 12(5):769-78. PubMed ID: 17713160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial.
    Sutinen J; Walker UA; Sevastianova K; Klinker H; Häkkinen AM; Ristola M; Yki-Järvinen H
    Antivir Ther; 2007; 12(1):97-105. PubMed ID: 17503753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda.
    van Griensven J; De Naeyer L; Mushi T; Ubarijoro S; Gashumba D; Gazille C; Zachariah R
    Trans R Soc Trop Med Hyg; 2007 Aug; 101(8):793-8. PubMed ID: 17467756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children.
    Sánchez Torres AM; Munoz Muniz R; Madero R; Borque C; García-Miguel MJ; De José Gómez MI
    Eur J Pediatr; 2005 May; 164(5):271-6. PubMed ID: 15650834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiretroviral-therapy-associated lipoatrophy: current status and future directions.
    Nolan D; Mallal S
    Sex Health; 2005; 2(3):153-63. PubMed ID: 16335543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case report.
    Parruti G; Toro GM
    BMC Infect Dis; 2005 Oct; 5():80. PubMed ID: 16202141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial.
    Calmy A; Bloch M; Wand H; Delhumeau C; Finlayson R; Rafferty M; Norris R; Hirschel B; Cooper DA; Carr A;
    HIV Med; 2010 Sep; 11(8):493-501. PubMed ID: 20236365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Weight loss after the first year of stavudine-containing antiretroviral therapy and its association with lipoatrophy, virological failure, adherence and CD4 counts at primary health care level in Kigali, Rwanda.
    van Griensven J; Zachariah R; Mugabo J; Reid T
    Trans R Soc Trop Med Hyg; 2010 Dec; 104(12):751-7. PubMed ID: 20889179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An update on the pharmacological strategies in the treatment of HIV-1-associated adipose redistribution syndromes.
    Mateo MG; Gutierrez Mdel M; Vidal F; Domingo P
    Expert Opin Pharmacother; 2014 Aug; 15(12):1749-60. PubMed ID: 24934336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current therapy of HIV.
    Potthoff AV; Brockmeyer NH
    J Dtsch Dermatol Ges; 2010 Jan; 8(1):45-56; quiz 57-8. PubMed ID: 20096060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?
    Nolan D
    Drug Saf; 2005; 28(12):1069-74. PubMed ID: 16329710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV and increased risk of cardiovascular diseases.
    Das S
    Sex Health; 2005; 2(4):219-21. PubMed ID: 16402668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Long-term tolerance. Preventing lipoatrophy].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():39. PubMed ID: 15011584
    [No Abstract]   [Full Text] [Related]  

  • 35. Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study.
    Mercier S; Gueye NF; Cournil A; Fontbonne A; Copin N; Ndiaye I; Dupuy AM; Cames C; Sow PS; Ndoye I; Delaporte E; Simondon KB
    J Acquir Immune Defic Syndr; 2009 Jun; 51(2):224-30. PubMed ID: 19339897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Editorial comment: the head bone is connected to the body bone.
    Fichtenbaum CJ
    AIDS Read; 2008 May; 18(5):265. PubMed ID: 18589481
    [No Abstract]   [Full Text] [Related]  

  • 37. Beyond lipodystrophy: will toxicity issues ever outweigh the benefits of HAART?
    Vella S; Palmisano L
    J HIV Ther; 2003 May; 8(2):27-8. PubMed ID: 15587479
    [No Abstract]   [Full Text] [Related]  

  • 38. Antiretroviral therapy: new solutions bring new problems.
    Atkins JL; Eccles S; Butler PE
    BMJ; 2003 Feb; 326(7384):337. PubMed ID: 12574054
    [No Abstract]   [Full Text] [Related]  

  • 39. "High" antiretroviral deintensification, a strategy to avoid drug interactions and unfavourable long-term effects of HAART.
    Lanzafame M; Piacentini D; Lattuada E; Rizzardo S; Chiesi S; Vento S
    Infect Dis (Lond); 2018 Oct; 50(10):788-790. PubMed ID: 29916752
    [No Abstract]   [Full Text] [Related]  

  • 40. Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection.
    Barbaro G
    Curr HIV Res; 2006 Jan; 4(1):79-85. PubMed ID: 16454713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.